大行評級|里昂:下調石藥集團目標價至12港元 重申“跑贏大市”評級
里昂發表研報指,石藥集團發佈第三季盈利預警,估計第三季成藥業務收入將按年下跌19%,純利料較去年同期減少50%。根據最新業績預吿,以及早前宣佈與阿斯利康合作協議中的1億美元預付款,以及其他項目的潛在預付款,目前里昂預計石藥今年全年盈利仍可達到55億至60億元。里昂將該集團2024至2026年收入預測下調6%、14%及12.1%,純利預測下調11.8%、17.4%及18.7%,目標價相應從12.5港元下調至12港元,重申“跑贏大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.